# Beyond Air, Inc. (XAIR) — capital_raise/atm_program [announced]
Source: SEC API (secapi.ai) · situation sit_7ec065966afe9e33e1d2 · retrieved 2026-08-12T21:26:50.669Z

## Overview
Beyond Air, Inc. is a medical device company developing nitric oxide delivery systems for respiratory conditions, with its lead product LungFit PH II pending FDA premarket approval.

On July 29, 2026, Beyond Air, Inc. entered into a securities purchase agreement with institutional investors and certain directors and executive officers to conduct a private placement. The Company agreed to issue 167,011 shares of common stock, pre-funded warrants to purchase 1,638,835 shares, Series A warrants to purchase 1,805,846 shares, and Series B warrants to purchase 1,805,846 shares. The combined purchase price per share and accompanying warrants was $5.66 for institutional investors and $5.76 for directors and executive officers. The private placement is expected to generate approximately $10.2 million in gross proceeds at closing, before deducting placement agent fees and other offering expenses. The closing was expected to occur on or about July 31, 2026.

## Terms
- Counterparty: Institutional investors and certain directors and executive officers · Deal value: $10.2M · Consideration: mixed · Price/share: $5.66

## Key dates
- Announced 2026-07-31 · Expected close 2026-07-31

## Timeline
- 2026-07-31 · 8-K (0001493152-26-035550): 8-K - Beyond Air, Inc. — *Beyond Air, Inc. is a medical device company developing nitric oxide delivery systems for respiratory conditions, with its lead product LungFit PH II pending FDA premarket approval.* On July 29, 2026, Beyond Air, Inc. entered into a securities purchase agreement with institutional investors and certain directors and executive officers to conduct a private placement. The Company agreed to issue 167,011 shares of common stock, pre-funded warrants to purchase 1,638,835 shares, Series A warrants to purchase 1,805,846 shares, and Series B warrants to purchase 1,805,846 shares. The combined purchase price per share and accompanying warrants was $5.66 for institutional investors and $5.76 for directors and executive officers. The private placement is expected to generate approximately $10.2 million in gross proceeds at closing, before deducting placement agent fees and other offering expenses. The closing was expected to occur on or about July 31, 2026.
  https://www.sec.gov/Archives/edgar/data/1641631/0001493152-26-035550.txt

## Citations
- 0001493152-26-035550 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226035550